Skip to main content

Advertisement

Table 5 MBL2 diplotypes and odds ratio for risk of being HCV RNA negative among injection drug users

From: MBL2and Hepatitis C Virus Infection among Injection Drug Users

  European Americans African Americans
Diplotype HCV RNA Negative HCV RNA Positive OR (95% CI) OR (95% CI)* HCV RNA Negative HCV RNA Positive OR (95% CI) OR (95% CI)*
YA/YA 32.1% 37.8% 1.00 1.00 30.3% 31.3% 1.00 1.00
XA/YA 25.7% 22.7% 1.36 (0.77–2.43) 1.36 (0.77–2.43) 18.0% 18.1% 1.01 (0.50–2.05) 1.01 (0.50–2.05)
YA/YO 16.5% 24.1% 0.81 (0.43–1.55) 0.99 (0.77–1.79) 29.2% 31.0% 0.96 (0.52–1.78) 1.00 (0.55–1.83)
XA/XA 5.5% 2.3% 2.74 (0.88–8.52) 2.3% 1.3% 2.08 (0.35–12.21)   
XA/YO 12.8% 7.3% 2.31 (1.07–5.02) 2.00 7.9% 10.0% 0.82 (0.33–2.08) 1.13
YO/YO 7.3% 5.8% 1.61 (0.65–4.03) (1.05–3.82) 12.4% 8.4% 1.49 (0.65–3.41) (0.57–2.24)
  1. *OR for grouped diplotypes. Diplotypes were ordered and grouped on the basis of previously reported serum MBL levels among Caucasians [13]. Mean serum MBL [mg/l] in that report were: YA/YA, 4.78; XA/YA, 2.83; YA/YO, 1.58; XA/XA, 1.39; XA/YO, 0.19; YO/YO, 0.05.